TY - JOUR
T1 - Sialic acid catabolism by N-acetylneuraminate pyruvate lyase is essential for muscle function
AU - Wen, Xiao-Yan
AU - Tarailo-Graovac, Maja
AU - Brand-Arzamendi, Koroboshka
AU - Willems, Anke
AU - Rakic, Bojana
AU - Huijben, Karin
AU - da Silva, Afitz
AU - Pan, Xuefang
AU - el-Rass, Suzan
AU - Ng, Robin
AU - Selby, Katheryn
AU - Philip, Anju Mary
AU - Yun, Junghwa
AU - Ye, X. Cynthia
AU - Ross, Colin J.
AU - Lehman, Anna M.
AU - Zijlstra, Fokje
AU - Abu Bakar, N.
AU - Drögemöller, Britt
AU - Moreland, Jacqueline
AU - Wasserman, Wyeth W.
AU - Vallance, Hilary
AU - van Scherpenzeel, Monique
AU - Karbassi, Farhad
AU - Hoskings, Martin
AU - Engelke, Udo
AU - de Brouwer, Arjan
AU - Wevers, Ron A.
AU - Pshezhetsky, Alexey V.
AU - van Karnebeek, Clara Dm
AU - Lefeber, Dirk J.
PY - 2018
Y1 - 2018
N2 - Sialic acids are important components of glycoproteins and glycolipids essential for cellular communication, infection, and metastasis. The importance of sialic acid biosynthesis in human physiology is well illustrated by the severe metabolic disorders in this pathway. However, the biological role of sialic acid catabolism in humans remains unclear. Here, we present evidence that sialic acid catabolism is important for heart and skeletal muscle function and development in humans and zebrafish. In two siblings, presenting with sialuria, exercise intolerance/muscle wasting, and cardiac symptoms in the brother, compound heterozygous mutations [chr1:182775324C>T (c.187C>T; p.Arg63Cys) and chr1:182772897A>G (c.133A>G; p.Asn45Asp)] were found in the N-acetylneuraminate pyruvate lyase gene (NPL). In vitro, NPL activity and sialic acid catabolism were affected, with a cell-type-specific reduction of N-acetyl mannosamine (ManNAc). A knockdown of NPL in zebrafish resulted in severe skeletal myopathy and cardiac edema, mimicking the human phenotype. The phenotype was rescued by expression of wild-type human NPL but not by the p.Arg63Cys or p.Asn45Asp mutants. Importantly, the myopathy phenotype in zebrafish embryos was rescued by treatment with the catabolic products of NPL: N-acetyl glucosamine (GlcNAc) and ManNAc; the latter also rescuing the cardiac phenotype. In conclusion, we provide the first report to our knowledge of a human defect in sialic acid catabolism, which implicates an important role of the sialic acid catabolic pathway in mammalian muscle physiology, and suggests opportunities for monosaccharide replacement therapy in human patients.
AB - Sialic acids are important components of glycoproteins and glycolipids essential for cellular communication, infection, and metastasis. The importance of sialic acid biosynthesis in human physiology is well illustrated by the severe metabolic disorders in this pathway. However, the biological role of sialic acid catabolism in humans remains unclear. Here, we present evidence that sialic acid catabolism is important for heart and skeletal muscle function and development in humans and zebrafish. In two siblings, presenting with sialuria, exercise intolerance/muscle wasting, and cardiac symptoms in the brother, compound heterozygous mutations [chr1:182775324C>T (c.187C>T; p.Arg63Cys) and chr1:182772897A>G (c.133A>G; p.Asn45Asp)] were found in the N-acetylneuraminate pyruvate lyase gene (NPL). In vitro, NPL activity and sialic acid catabolism were affected, with a cell-type-specific reduction of N-acetyl mannosamine (ManNAc). A knockdown of NPL in zebrafish resulted in severe skeletal myopathy and cardiac edema, mimicking the human phenotype. The phenotype was rescued by expression of wild-type human NPL but not by the p.Arg63Cys or p.Asn45Asp mutants. Importantly, the myopathy phenotype in zebrafish embryos was rescued by treatment with the catabolic products of NPL: N-acetyl glucosamine (GlcNAc) and ManNAc; the latter also rescuing the cardiac phenotype. In conclusion, we provide the first report to our knowledge of a human defect in sialic acid catabolism, which implicates an important role of the sialic acid catabolic pathway in mammalian muscle physiology, and suggests opportunities for monosaccharide replacement therapy in human patients.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85063247012&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/30568043
U2 - https://doi.org/10.1172/jci.insight.122373
DO - https://doi.org/10.1172/jci.insight.122373
M3 - Article
C2 - 30568043
SN - 2379-3708
VL - 3
JO - JCI Insight
JF - JCI Insight
IS - 24
ER -